Radiation plus immunotherapy for advanced lung cancer
Treatments studied
Part of Cancer, Immune system & allergy, Lungs & breathing clinical trials.
This trial tests whether adding two immunotherapy drugs (cemiplimab and fianlimab) to standard radiation and chemotherapy can help treat locally advanced non-small cell lung cancer that hasn't been treated before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer that hasn't been treated before and can't be surgically removed.
- Your cancer is stage II (unresectable) or stage III, and you're eligible for standard chemo and radiation.
- You have a tumor sample tested for PD-L1 levels.
- You have adequate organ function (kidneys, liver, blood counts) and an ECOG performance status of 0-2.
- You have no known EGFR or ALK mutations (gene changes that respond to different treatments).
- You haven't had prior immunotherapy with PD-1, PD-L1, or LAG-3 inhibitors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized chemotherapy approach for people with early-stage (stage II–IIIB) non-small cell lung cancer that can be removed with surgery. It uses the tumor's PD-L1 level (a marker that helps the immune system attack cancer) to guide treatment before surgery, aiming to improve outcomes.
This trial tests a combination of radiation, immunotherapy (QL1706), and chemotherapy given before surgery for non-small-cell lung cancer that can be removed. It aims to see if this approach can shrink the tumor and improve outcomes.
This trial tests combining immunotherapy with chemotherapy for people with stage III non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink the tumor and improve outcomes.
This trial compares two treatment approaches before surgery for non-small cell lung cancer (NSCLC): radiation plus immunotherapy versus chemotherapy plus immunotherapy. The goal is to see which combination works better to shrink the tumor before it is removed.
This trial tests a combination of immunotherapy (cemiplimab) and chemotherapy for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. It looks at whether this treatment works better when certain immune cells in the blood are high.
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
Hear when a new Locally Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.